Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs
 carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with
 anaplastic prostate cancer. Patients who continue to have advanced disease will be switched
 to etoposide (VePesid) plus cisplatin (Platinol-AQ) to study how effective this second line
 of chemotherapy is in the treatment of patients iwth anaplastic prostate cancer.

 The side effects, characteristics of patients who respond, and overall survival will also be
 studied.
Carboplatin is designed to interfere with the growth of cancer cells by stopping cell
 division.

 Docetaxel is designed to stop the growth of cancer cells, which may cause the cells to die.
 It is believed to be weakly effective at killing blood vessels in cancer cells as well.

 Etoposide is a drug that has been shown to interfere with the growth of cancer cells, which
 may cause them to eventually die.

 Cisplatin has an atom at its center that contains platinum. The platinum is supposed to
 poison the cancer cells, which may cause them to eventually die.

 If you are found to be eligible to take part in this study, you will receive carboplatin plus
 docetaxel by a vein or central line in a vein. You will receive carboplatin over about 30
 minutes and docetaxel over about 60 minutes. You will receive this therapy combination on Day
 1 of each cycle of therapy (every 3-4 weeks), depending on the recovery of your bone marrow.
 These 3-4 weeks are considered 1 cycle of therapy. This therapy combination will be given on
 an outpatient basis. If you experience any side effects, your dose of docetaxel plus
 carboplatin may be decreased.

 You will be given dexamethasone, by a vein in your arm, by central line in a vein, or by
 mouth, before your therapy begins with docetaxel plus carboplatin. Dexamethasone will help
 decrease bone marrow inflammation. You will also be given a colony stimulating factor (when
 the doctor thinks it is needed) to help maintain your white blood cell count to help decrease
 any chance of infection. Colony stimulating factor will be given as a subcutaneous injection
 (under the skin), at the discretion of the treating physician, during therapy.

 You will have about 2-3 tablespoons of blood drawn at the beginning of each cycle of therapy
 for routine blood tests and blood tests for cancer markers. You will be asked about any
 medications you are currently taking.

 At the end of the first 2 cycles of therapy, you will have some or all of the scans
 (performed during the screening visit) repeated to evaluate your disease. If your disease is
 responding well to the therapy, you will continue on docetaxel plus carboplatin for 2 more
 cycles. In this case, you will continue receive the study combination until your doctor
 thinks you have received the most benefit. You will then be followed with some or all of the
 scans (performed during the screening visit) every 2 months unless your cancer progresses
 (gets worse) or until you begin on a new therapy after your treatment has ended on this
 study.

 If you are already taking hormone therapy with an luteinizing hormone-releasing hormone
 (LHRH) agonist (such as Lupron or Zoladex) , you will continue taking these medications. If
 you are taking an anti-androgen drug (such as Casodex), you should stop taking it.

 If your cancer is progressing after having had a maximal response, if your disease does not
 respond after 2 courses of therapy, or if you are not able to tolerate some side effects of
 docetaxel plus carboplatin, your chemotherapy will be switched to etoposide plus cisplatin.
 If this is the case, etoposide plus cisplatin will be given to you by a vein in your arm or
 central line in a vein. You will receive this therapy combination once a day (etoposide over
 60 minutes and cisplatin over 2 hours) for the first 3 days during each cycle of therapy, and
 then therapy will be repeated every 3 to 4 weeks.

 Therapy with etoposide plus cisplatin will be continued as long as your cancer responds well
 to this therapy and you are not experiencing any intolerable side effects. If you experience
 any side effects, your dose of etoposide plus cisplatin may be decreased. This treatment
 combination may be given on an inpatient basis.

 You will be removed from this study if your disease gets worse or you experience any
 intolerable side effects.

 If you come off this study because you completed therapy, your disease got worse, or you
 experienced intolerable side effects, you will have an end-of-study visit. During this visit,
 you will have blood drawn (about 3 tablespoons) for routine tests. You will have a complete
 physical exam, including measurement of your vital signs. You will also have your complete
 medical history recorded and you will be asked about any medications you are currently
 taking. You will have imaging scans to evaluate your disease (similar to those at screening)
 if they have not been done in the last 28 days.

 Once you are no longer on this study, the research staff will periodically check up on you
 (about every 6 months). This update will consist of a phone call, an e-mail, or a review of
 your medical and/or other records. No clinic visits or additional diagnostic studies are
 required by the study. If contacted by phone, the call would only last a few minutes.

 This is an investigational study. Carboplatin, docetaxel, etoposide, and cisplatin are all
 commercially available and approved by the FDA. Up to 120 patients will take part in this
 multicenter study. Up to 90 will be enrolled at MD Anderson.
Inclusion Criteria:

 1. Patient must have androgen independent Stage IV prostate cancer, with anaplastic
 features as defined by at least one of the following: a) Histologic evidence of small
 cell(pure/mixed), locally advanced or metastatic; b) Any of the following at Dx:
 exclusive visceral mets, predominant lytic mets, bulky ( >/= 5 cm) lymphadenopathy, or
 bulky ( >/= 5 cm) high-grade (Gleason >/= 8) tumor mass in the prostate/pelvis c) Low
 prostate-specific antigen (PSA) at diagnosis (Dx) + high volume bone mets.

 2. (#1 cont'd) d) Neuroendocrine markers in histology (+ Chromogranin A and/or
 Synaptophysin) or serum (abnl high serum Chromogranin A or Bombesin) at Dx or at
 progression plus any of the following: elevated serum lactate dehydrogenase (LDH),
 malignant HyperCa+, or elevated serum Carcinoembryonic Antigen (CEA) in the absence of
 other etiologies. e) Short interval (< 6 months) to androgen-independent progression
 following initiation of hormonal therapy with or without presence of neuroendocrine
 markers.

 3. Patients with small cell carcinoma on histology are not required to have received
 prior androgen deprivation therapy (ADT). All other patients must have evidence of
 disease progression while on ADT or an unsatisfactory response to >/= 1 month of
 castration, as defined by lack of symptom control and/or serum tumor marker response
 of < 20% (confirmed by a second value drawn on a different day).

 4. Zubrod performance status of </= 2.

 5. Normal EKG or, if EKG is suggestive of cardiomyopathy, patient has a resting Left
 Ventricular Ejection Fraction (LEVF) >/= 50% within 4 months.

 6. Patient has all of the following pretreatment laboratory data within 14 days before
 registration: • Absolute neutrophil count (ANC) >=1,500/mm^3.(unless due to bone
 marrow infiltration by tumor, in which case ANC >/= 500/mm^3 are allowed). • Platelets
 >=100,000/mm^3 (unless due to bone marrow infiltration by tumor, in which case
 platelets >/= 20,000/mm^3 are allowed)

 7. (#7 cont'd) • Total bilirubin </= 2 mg/dl; if greater, conjugated bilirubin should be
 <= 1.0 mg/dL, • serum glutamate pyruvate transaminase (SGPT) (ALT) and/or serum
 glutamate oxaloacetate transaminase (SGOT) (AST) </= 4 times the upper limit of normal
 (ULN). • Creatinine clearance >/= 40 (either measured or calculated by Cockcroft
 formula) • Castrate levels of serum testosterone (</= 50ng/mL) if no small cell
 elements on histology. (If small cell, testosterone > 50ng/mL)

 8. Patient has given voluntary written informed consent before performance of any
 study-related procedure not part of standard medical care.

 Exclusion Criteria:

 1. Immunotherapy or chemotherapy within four weeks (nitrosoureas within six weeks) of
 registration.

 2. 2 or more prior chemotherapy regimens (ketoconazole, aminoglutethimide or dutasteride
 do not count as chemotherapy for this trial).

 3. Prior Platinum, Etoposide, or Taxane-based therapy that was completed less than 6
 months from registration.

 4. Samarium-153 within four weeks of registration, or Strontium-89 within 12 weeks of
 registration. Patients who have received 2 or more doses of bone-seeking radioisotopes
 are not eligible.

 5. Patient has not recovered from all serious toxic effects of previous chemotherapy,
 radiation or antibody therapy, or from previous major surgery.

 6. Patients with symptomatic and untreated brain metastases or central nervous system
 disease will be excluded. Patients with untreated, asymptomatic brain metastasis (not
 requiring corticosteroid treatment for control of central nervous system (CNS)
 symptoms) may be eligible, at the discretion of the MDACC Principal Investigator.
 Patients with treated brain metastases are eligible.

 7. Patient with significant atherosclerotic disease, as defined by: a) myocardial
 infarction within six months of enrollment. Current uncontrolled/unstable angina
 pectoris or electrocardiographic evidence of acute ischemia b) clinically significant
 ventricular arrhythmias c) symptomatic congestive heart failure (NYHA Class III)

 8. Patient has >= Grade 2 peripheral neuropathy.

 9. Patient has renal insufficiency with cranial cruciate ligament (CrCL) < 40 ml/min with
 non-correctable etiologies.

 10. Patient has an uncontrolled intercurrent illness (e.g., active infection).

 11. Patient has another serious medical or psychiatric illness that could, in the
 investigator's opinion, potentially interfere with the patient's ability to provide
 informed consent or with the completion of treatment according to this protocol.